These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7483805)

  • 1. Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers.
    Weber J; Cheinsong-Popov R; Callow D; Adams S; Patou G; Hodgkin K; Martin S; Gotch F; Kingsman A
    Vaccine; 1995 Jun; 13(9):831-4. PubMed ID: 7483805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.
    Martin SJ; Vyakarnam A; Cheingsong-Popov R; Callow D; Jones KL; Senior JM; Adams SE; Kingsman AJ; Matear P; Gotch FM
    AIDS; 1993 Oct; 7(10):1315-23. PubMed ID: 8267904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
    J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gag-specific immune responses after immunization with p17/p24:Ty virus-like particles in HIV type 1-seropositive individuals.
    Klein MR; Veenstra J; Holwerda AM; Roos MT; Gow I; Patou G; Coutinho RA; De Wolf F; Miedema F
    AIDS Res Hum Retroviruses; 1997 Mar; 13(5):393-9. PubMed ID: 9075480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.
    Peters BS; Cheingsong-Popov R; Callow D; Foxall R; Patou G; Hodgkin K; Weber JN
    J Infect; 1997 Nov; 35(3):231-5. PubMed ID: 9459393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression.
    Lindenburg CE; Stolte I; Langendam MW; Miedema F; Williams IG; Colebunders R; Weber JN; Fisher M; Coutinho RA
    Vaccine; 2002 May; 20(17-18):2343-7. PubMed ID: 12009290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decline in CTL and antibody responses to HIV-1 p17 and p24 antigens in HIV-1-infected hemophiliacs irrespective of disease progression. A 5-year follow-up study.
    O'Toole CM; Lowdell MW; Chargelegue D; Colvin BT
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1361-8. PubMed ID: 1281655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons.
    Veenstra J; Williams IG; Colebunders R; Dorrell L; Tchamouroff SE; Patou G; Lange JM; Weller IV; Goeman J; Uthayakumar S; Gow IR; Weber JN; Coutinho RA
    J Infect Dis; 1996 Oct; 174(4):862-6. PubMed ID: 8843231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression.
    Chargelegue D; Stanley CM; O'Toole CM; Colvin BT; Steward MW
    Clin Exp Immunol; 1995 Feb; 99(2):175-81. PubMed ID: 7851008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and persistence of antibody titers to recombinant HIV-1 core and matrix proteins in HIV-1 infection.
    Janvier B; Mallet F; Cheynet V; Dalbon P; Vernet G; Besnier JM; Choutet P; Goudeau A; Mandrand B; Barin F
    J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):898-903. PubMed ID: 8315575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificities.
    Koup RA; Pikora CA; Luzuriaga K; Brettler DB; Day ES; Mazzara GP; Sullivan JL
    J Exp Med; 1991 Dec; 174(6):1593-600. PubMed ID: 1744586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody recognition of synthetic peptides mimicking immunodominant regions of HIV-1 p24 and p17 proteins.
    Lottersberger J; Salvetti JL; Beltramini LM; Tonarelli G
    Rev Argent Microbiol; 2004; 36(4):151-7. PubMed ID: 15786866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine.
    Van Braeckel E; Desombere I; Clement F; Vandekerckhove L; Verhofstede C; Vogelaers D; Leroux-Roels G
    Vaccine; 2013 Aug; 31(36):3739-46. PubMed ID: 23707169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.
    Kelleher AD; Roggensack M; Jaramillo AB; Smith DE; Walker A; Gow I; McMurchie M; Harris J; Patou G; Cooper DA
    AIDS; 1998 Jan; 12(2):175-82. PubMed ID: 9468366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel method for the purification of HIV-1 p24 protein from hybrid Ty virus-like particles (Ty-VLPs).
    Gilmour JE; Senior JM; Burns NR; Esnouf MP; Gull K; Kingsman SM; Kingsman AJ; Adams SE
    AIDS; 1989 Nov; 3(11):717-23. PubMed ID: 2559750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants.
    Klenerman P; Rowland-Jones S; McAdam S; Edwards J; Daenke S; Lalloo D; Köppe B; Rosenberg W; Boyd D; Edwards A
    Nature; 1994 Jun; 369(6479):403-7. PubMed ID: 7515165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal conditions of immune complex transfer enzyme immunoassays for antibody IgGs to HIV-1 using recombinant p17, p24, and reverse transcriptase as antigens.
    Hashida S; Ishikawa S; Hashinaka K; Nishikata I; Oka S; Shimada K; Saito A; Takamizawa A; Shinagawa H; Ishikawa E
    J Clin Lab Anal; 1998; 12(2):98-107. PubMed ID: 9524294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential maturation of avidity of IgG antibodies to gp41, p24 and p17 following infection with HIV-1.
    Thomas HI; Wilson S; O'Toole CM; Lister CM; Saeed AM; Watkins RP; Morgan-Capner P
    Clin Exp Immunol; 1996 Feb; 103(2):185-91. PubMed ID: 8565298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A longitudinal study of the IgG antibody response to HIV-1 p17 gag protein in HIV-1+ patients with haemophilia: titre and avidity.
    Chargelegue D; O'Toole CM; Colvin BT
    Clin Exp Immunol; 1993 Sep; 93(3):331-6. PubMed ID: 8370162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.